Suggested remit - To appraise the clinical and cost effectiveness of mogamulizumab within its marketing authorisation for treated mycosis fungoides or Sézary syndrome cutaneous T-cell lymphoma
 
Status In progress
Process STA 2018
ID number 1405

Provisional Schedule

Committee meeting: 1 07 July 2020
Expected publication 16 September 2020

Project Team

Project lead Louise Jafferally

Email enquiries

Evidence Review Group / Assessment Group Kleijnen Systematic Reviews Ltd

Consultees

Companies sponsors Kyowa Kirin (mogamulizumab)
Others Department of Health and Social Care
  NHS England
  NHS North Somerset CCG
  NHS Vale of York CCG
  Welsh Government
Patient carer groups African Caribbean Leukaemia Trust
  Anthony Nolan
  Black Health Agency
  Bloodwise
  British Skin Foundation
  Cancer Black Care
  Cancer Equality
  Cancer52
  DKMS
  Helen Rollason Cancer Charity
  Independent Cancer Patients Voice
  Leukaemia Cancer Society
  Leukaemia CARE
  Lymphoma Action
  Macmillan Cancer Support
  Maggie’s Centres
  Marie Curie
  Muslim Council of Britain
  South Asian Health Foundation
  Specialised Healthcare Alliance
  Tenovus Cancer Care
  WMUK
Professional groups Association of Cancer Physicians
  British Association of Dermatologists
  British Association of Skin Cancer Specialist Nurses
  British Committee for Standards in Haematology
  British Dermatological Nursing Group
  British Geriatrics Society
  British Institute of Radiology
  British Psychosocial Oncology Society
  British Society for Haematology
  Cancer Research UK
  Melanoma Focus
  Primary Care Dermatology Society
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Radiologists
  Royal Pharmaceutical Society
  Royal Society of Medicine
  Society and College of Radiographers
  UK Clinical Pharmacy Association
  UK Oncology Nursing Society

Commentators

Associated public health groups Public Health England
  Public Health Wales
Comparator companies Accord Healthcare (methotrexate)
  ADVANZ Pharma (methotrexate)
  Cipla EU (methotrexate)
  Eisai (bexarotene)
  Hospira UK (methotrexate)
  medac (methotrexate)
  Nordic Pharma (methotrexate)
  Orion Pharma (methotrexate)
  Pfizer (methotrexate)
  Roche Products (interferon alfa-2a)
  Rosemont Pharmaceuticals (methotrexate)
  Sandoz (methotrexate)
  Takeda (brentuximab vedotin)
  Therakind (methotrexate)
General commentators All Wales Therapeutics & Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare Products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Alliance
  NHS Confederation
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups British Epidermo-Epidermiology Society
  British Society for Dermatological Surgery
  Cochrane Haematological Malignancies Group
  Cochrane Skin Group
  Genomics England
  Institute of Cancer Research
  Leuka
  Leukaemia Busters
  Lymphoma Research Trust
  MRC Clinical Trials Unit
  National Cancer Research Institute
  National Cancer Research Network
  National Institute for Health Research
  Skin Cancer Research Fund
  Skin Treatment and Research Trust

Timeline

Key events during the development of the guidance:

Date Update
24 October 2019 Invitation to participate
09 May 2019 - 07 June 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
27 March 2019 As you will be aware, the Department for Health and Social Care has asked NICE to conduct an appraisal of mogamulizumab for previously treated cutaneous T-cell lymphoma (mycosis fungoides or Sézary syndrome). Please note that following on from advice received from the company the timelines for this appraisal have been revised. We now anticipate that the appraisal will begin during early October 2019 when we will write to you about how you can get involved.
07 June 2018 This appraisal has been rescheduled following an update from the company. The appraisal is now anticipated to begin in early July 2019 with a submission deadline anticipated late August/early September 2019. This delay means that this appraisal will be removed from the NICE’s reporting targets for timeliness. In addition, through this request for delay the company accepts that this drug will not be eligible to receive interim CDF funding from the date of marketing authorization.
12 March 2018 - 11 April 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
05 December 2017 In progress, Topic referred

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance